Financial year Results for the year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences reported a steep fall in revenues and widening losses for FY25. Standalone revenue from operations dropped to ₹8,991.01 lakhs from ₹13,136.88 lakhs a year ago (down ~31.5%), while consolidated revenue fell to ₹9,284.66 lakhs from ₹14,610.97 lakhs (down ~36.5%). Standalone net loss widened to ₹1,034.29 lakhs (vs ₹864.81 lakhs loss in FY24), and consolidated net loss deepened to ₹1,241.33 lakhs (vs ₹1,014.30 lakhs). Q4 also remained in the red, with standalone loss of ₹193.87 lakhs. The company booked exceptional items of ₹173.51 lakhs. Total borrowings rose to ₹6,780.33 lakhs (standalone), nearly matching total equity of ₹6,680.90 lakhs, and operating cash flow stayed negative at ₹(229.27) lakhs. Statutory auditor M/s Khurana Sharma & Co. issued an unmodified opinion.
Negative for shareholders — shrinking top line, mounting losses, rising debt and weak cash generation point to sustained pressure on profitability. Stock may face downside sentiment unless the company demonstrates a credible turnaround.